[Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014]

Ophthalmologe. 2015 Mar;112(3):237-45. doi: 10.1007/s00347-014-3222-x.
[Article in German]
No abstract available

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Bevacizumab / administration & dosage
  • Drug Administration Schedule
  • Germany
  • Humans
  • Ophthalmology / standards*
  • Practice Guidelines as Topic*
  • Ranibizumab / administration & dosage
  • Receptors, Vascular Endothelial Growth Factor / administration & dosage
  • Recombinant Fusion Proteins / administration & dosage
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*
  • Wet Macular Degeneration / diagnosis*
  • Wet Macular Degeneration / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab